Life sciences

SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES

Retrieved on: 
Tuesday, March 31, 2020

SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrentos COVID-19 therapeutic product candidates.

Key Points: 
  • SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrentos COVID-19 therapeutic product candidates.
  • Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases.
  • UTMB is an institution in the University of Texas System and a member of the Texas Medical Center.
  • Forward-looking statements include statements regarding the preclinical testing of Sorrentos COVID-19 therapeutic product candidates; the safety and efficacy of Sorrentos COVID-19 therapeutic product candidates; the therapeutic potential of Sorrentos COVID-19 therapeutic product candidates for SARS-CoV-2 and COVID-19 disease; and Sorrentos potential position in the vaccine industry.

Former J&J/Biosense Webster Exec, Roy Tanaka, Joins S4 Medical's Board of Directors

Retrieved on: 
Tuesday, March 31, 2020

S4 Medical has developed a novel catheter called the "esolution" that utilizes a proprietary approach to deviate the esophagus.

Key Points: 
  • S4 Medical has developed a novel catheter called the "esolution" that utilizes a proprietary approach to deviate the esophagus.
  • A seasoned executive in the electrophysiology industry, Tanaka brings years of experience to S4.
  • Tanaka joined Biosense Webster, a Johnson & Johnson company, in 1997 as U.S. president, and became its worldwide president in 2004 until his retirement in 2008.
  • "S4 is on a fast pace to success and we are excited to have Roy on the team.

Global Capnography Devices Market 2020-2024 | Evolving Opportunities with Becton, Dickinson and Co. and Drägerwerk AG & Co. KGaA | Technavio

Retrieved on: 
Tuesday, March 31, 2020

Furthermore, the economic cost of disposables has encouraged vendors operating in the market to offer lucrative discounts on capnography instruments.

Key Points: 
  • Furthermore, the economic cost of disposables has encouraged vendors operating in the market to offer lucrative discounts on capnography instruments.
  • This allows vendors to maintain a steady stream of revenue, leading to the growth of the market.
  • The launch of favorable regulatory guidelines for the use of capnography is further anticipated to boost the growth of the global capnography devices market.
  • Major Five Capnography Devices Companies:
    The company operates through key business segments including BD Medical, BD Life Sciences, and BD Interventional.

2020 World Molecular Diagnostic Analyzer and Reagent Forecasts for 100 Tests: Americas, EMEA, APAC--A 68-Country Analysis--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing

Retrieved on: 
Tuesday, March 31, 2020

NEW YORK, March 31, 2020 /PRNewswire/ -- 2020 World Molecular Diagnostic Analyzer and Reagent Forecasts for 100 Tests: Americas, EMEA, APAC--A 68-Country Analysis--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing

Key Points: 
  • NEW YORK, March 31, 2020 /PRNewswire/ -- 2020 World Molecular Diagnostic Analyzer and Reagent Forecasts for 100 Tests: Americas, EMEA, APAC--A 68-Country Analysis--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing
    This new 68-country survey provides granular data and analysis not available from any other source.
  • The report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years.
  • The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry.
  • - Sales and market shares of key suppliers of molecular diagnostic reagent kits and components in major markets.

2020 Generic and Specialty Drug Companies: Capabilities, Goals and Strategies

Retrieved on: 
Tuesday, March 31, 2020

In the dynamic and fragmented Generic and Specialty Drug industry, besieged by intense competition and rapid change of technological innovations, the ability to anticipate new product introductions and marketing strategies is particularly important...and can spell the difference between success and failure.

Key Points: 
  • In the dynamic and fragmented Generic and Specialty Drug industry, besieged by intense competition and rapid change of technological innovations, the ability to anticipate new product introductions and marketing strategies is particularly important...and can spell the difference between success and failure.
  • Our collection of strategic assessments of leading Generic and Specialty Drug companies provides significant competitor information, analysis and insight critical to the development and implementation of effective business, marketing and R&D programs.
  • The assessments include latest organizational and management developments, acquisitions and divestitures, marketing tactics, financial results, strengths and weaknesses, and strategic directions.

Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD

Retrieved on: 
Tuesday, March 31, 2020

Sofinnova Investments , a clinical stage biopharmaceutical investment firm, announces the promotions of Maha Katabi, PhD, CFA to General Partner and Sarah Bhagat, PhD to Partner.

Key Points: 
  • Sofinnova Investments , a clinical stage biopharmaceutical investment firm, announces the promotions of Maha Katabi, PhD, CFA to General Partner and Sarah Bhagat, PhD to Partner.
  • Maha Katabi, PhD, CFA who joined Sofinnova in April 2019, has been essential to the firms executive team in addition to enhancing the teams geographic investment coverage across North America and Europe.
  • Prior to joining Sofinnova, Maha co-invested with Sofinnova in multiple companies, including Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND), and Trius Therapeutics (acquired by Cubist).
  • These promotions reflect the immense value and distinctive perspectives Maha and Sarah bring to our partnership, says Mike Powell, PhD, and General Partner of Sofinnova.

MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma

Retrieved on: 
Tuesday, March 31, 2020

MEI is currently conducting TIDAL (Trials of PI3KDeltAin Non-Hodgkin'sLymphoma), a Phase 2 trial evaluating ME-401 in patients with relapsed or refractory follicular lymphoma ("FL").

Key Points: 
  • MEI is currently conducting TIDAL (Trials of PI3KDeltAin Non-Hodgkin'sLymphoma), a Phase 2 trial evaluating ME-401 in patients with relapsed or refractory follicular lymphoma ("FL").
  • "We are pleased to report that we have received Fast Track designation for ME-401.
  • Fast track designated products are eligible for consideration of priority review if supported by clinical data at the time of NDA submission.
  • MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer.

Global Single Cell Sequencing Market Report 2020 - Emergence of New Sequencing Techniques, Advancements in Cell Isolation Techniques - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 31, 2020

The global single cell sequencing market growth has been primarily attributed to the major drivers in this market such as increasing focus on non-invasive therapy by decreasing dependence on trial and error medicine, analysis of gene expression level and protein expression level simultaneously through single cell genomics, the emergence of new sequencing techniques, and advancements in cell isolation techniques.

Key Points: 
  • The global single cell sequencing market growth has been primarily attributed to the major drivers in this market such as increasing focus on non-invasive therapy by decreasing dependence on trial and error medicine, analysis of gene expression level and protein expression level simultaneously through single cell genomics, the emergence of new sequencing techniques, and advancements in cell isolation techniques.
  • What are the major market drivers, challenges, and opportunities in the global single cell sequencing market?
  • What are the underlying structures resulting in the emerging trends within the global single cell sequencing market?
  • Who are the key manufacturers the global single cell sequencing market, and what are their contributions?

Global Digital Pathology Market (2020 to 2025) - High Scope of Growth in Emerging Economies Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 31, 2020

However, the high cost of digital pathology systems is expected to restrict market growth to a certain extent.

Key Points: 
  • However, the high cost of digital pathology systems is expected to restrict market growth to a certain extent.
  • By type, the human pathology segment accounted for the largest share of the digital pathology market in 2019.
  • On the basis of type, the global digital pathology market is segmented into human and veterinary pathology.
  • The human pathology segment accounted for the largest share of the digital pathology market in 2019.

Hikma confirms favourable ruling in generic Vascepa® patent suit

Retrieved on: 
Tuesday, March 31, 2020

Hikma is working closely with the U.S. Food and Drug Administration (FDA) to gain approval for its Abbreviated New Drug Application (ANDA) for its generic version of Vascepa.

Key Points: 
  • Hikma is working closely with the U.S. Food and Drug Administration (FDA) to gain approval for its Abbreviated New Drug Application (ANDA) for its generic version of Vascepa.
  • The company is evaluating its options for launching the product following FDA approval, including an at-risk launch in the event the District Court's decision is appealed.
  • "We look forward to providing patients and health care providers in the US with a generic version of this important medicine."
  • According to IQVIA, US sales of Vascepawere approximately $919 million in the 12 months ending February 2020.